Effects of CARD on the final body weight, testicular weight, blood glucose, insulin levels, and HOMA-IR in all experimental groups
Variable | Final body weight (gm) |
Testicular weight (gm) |
Fasting blood glucose (mg/dl) | Fasting insulin (µIU/ml) |
HOMA-IR |
---|---|---|---|---|---|
Control | 282.56 ± 1.76 | 1.68 ± 0.09 | 74.26 ± 2.98 | 15.04 ± 1.31 | 2.76 |
CARD | 280.06 ± 2.85 | 1.71 ± 0.08 | 72.15 ± 2.25 | 16.09 ± 1.02 | 2.87 |
DM | 221.33 ± 2.33 |
1.09 ± 0.07 |
384.27 ± 3.54 |
5.78 ± 1.28 |
5.48 |
DM + GLIB | 255.66 ± 3.51 |
1.29 ± 0.08 |
143.32 ± 4.76 |
12.61 ± 1.18 |
4.46 |
DM + CARD | 241.733 ± 2.59 |
1.49 ± 0.08 |
157.74 ± 3.79 |
11.89 ± 1.19 |
4.63 |
DM + GLIB + CARD | 272.41 ± 2.31 |
1.56 ± 0.09 |
97.72 ± 4.37 |
14.57 ± 1.40 |
3.51 |
Values are presented as mean ± SD. CARD, normal rat supplemented with cardamonin; HOMA-IR, homeostatic model assessment of insulin resistance; DM, untreated diabetic group; DM + GLIB, diabetic rats treated with glibenclamide; DM + CARD, diabetic rats treated with cardamonin; DM + GLIB + CARD, diabetic rats treated with both glibenclamide and cardamonin. Test used: One-way ANOVA followed by